Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adipic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.38 |
| ▸ | PPARG | P37231 | 6/20 | 0.38 |
| ▸ | PPARD | Q03181 | 6/20 | 0.38 |
| ▸ | PPARA | Q07869 | 6/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metformin SCHEMBL2815209 | 0.96 | SLC22A6 (0.41) | LMNATSHRNFKB1PMP22AKR1B1 | |
| Metformin SCHEMBL1558869 | 0.92 | PHF8 (0.41) | LMNA | |
| Metformin SCHEMBL7647374 | 0.92 | PHF8 (0.41) | LMNA | |
| Decanoic Acid SCHEMBL6051781 | 0.92 | GPR84 (0.53) | LMNATSHRAKR1B1GPR84PPARG | |
| Stearic Acid SCHEMBL6129908 | 0.92 | GPR84 (0.53) | LMNATSHRAKR1B1GPR84PPARG | |
| Palmitic Acid SCHEMBL6051750 | 0.92 | GPR84 (0.53) | LMNATSHRAKR1B1GPR84PPARG | |
| Dodecanoate SCHEMBL6051694 | 0.92 | GPR84 (0.53) | LMNATSHRAKR1B1GPR84PPARG | |
| Metformin SCHEMBL7123890 | 0.91 | PHF8 (0.39) | LMNA | |
| Dodecanoate SCHEMBL6056079 | 0.89 | GPR84 (0.50) | LMNATSHRAKR1B1GPR84PPARG | |
| Metformin SCHEMBL991940 | 0.87 | FFAR3 (0.46) | TSHRAKR1B1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203418-B1 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANALL BIOPHARMA CO LTD (KR) | 2017-10-25 | — | — | EP | disclosed |
| CN-101855204-B | N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same | HANALL BIOPHARMA CO LTD | 2013-09-11 | — | — | CN | disclosed |
| US-8076377-B2 | N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same | HANALL PHARMACEUTICAL COMPANY, LTD. (KR) | 2011-12-13 | — | — | US | disclosed |
| CN-101855204-A | N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same | HANALL PHARMACEUTICAL COMPANY LTD | 2010-10-06 | — | — | CN | disclosed |
| US-20100249241-A1 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANALL PHARMACEUTICAL COMPANY, LTD. (KR) | 2010-09-30 | — | — | US | disclosed |
| EP-2203418-A2 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Hanall Pharmaceutical Company LTD. (KR) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009038396-A2 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANALL PHARMACEUTICAL COMPANY. LTD (KR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249241-A1 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | TNNC1, TP53, CAD | SLC6A2 4474/4885SLC6A3 3687/4885LMNA 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.